Who Optimizes SG&A Costs Better? Amgen Inc. or Galapagos NV

Optimizing SG&A: A Tale of Two Biotech Giants

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Amgen Inc. and Galapagos NV, two prominent players, showcase contrasting strategies over the past decade. From 2014 to 2023, Amgen's SG&A expenses grew by approximately 31%, peaking in 2023. In contrast, Galapagos NV's expenses surged by over 900%, reflecting its aggressive expansion strategy. Despite this, Amgen's expenses remain significantly higher, indicating its larger operational scale. The data suggests that while Amgen focuses on maintaining a steady growth trajectory, Galapagos NV is investing heavily in its future. This divergence highlights the strategic choices companies make in balancing cost management with growth ambitions. Investors and industry watchers should consider these trends when evaluating the long-term potential of these biotech giants.